Argenx presents new Efgartigimod data at EULAR 2025
Confident Investing Starts Here:
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Currax Expands Access to FDA-Approved Obesity Treatment with Brand Name Contrave® with New Cash Price Available via GoodRx
New cash pay program offers Contrave, the #1 branded oral non-GLP-1 weight loss medication brand, for as low as $199 per month* BRENTWOOD, Tenn., July 15, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax"), a specialty biopharmaceutical company and manufacturer of the #1 branded oral non-GLP-1 weight loss medication brand CONTRAVE® (naltrexone HCl/bupropion HCl), announces today the launch of its latest cost saving initiative with GoodRx, the leading platform for medication savings in the U.S. The national access program introduces a cash pay prescription offer for Contrave, expanding access to affordable weight management medication for more patients, regardless of insurance. According to the CDC, more than 40% of U.S. adults are living with obesity, yet cost and coverage barriers often limit access to effective treatment options. Now, patients can access Contrave at a cash price of $199 via GoodRx, regardless of insurance status, allowing them to fill their Contrave prescription at over 70,000 pharmacies across the United States. Through the program, millions of U.S. adults living with obesity and weight-related health issues will have access to obesity treatment. "At Currax, we truly believe in access for all and putting patients at the center of everything we do," said George Hampton, CEO of Currax Pharmaceuticals. "By making our cash price available through GoodRx, we are continuing to reduce barriers and provide an easy path for patients to get the treatment they need to manage their weight and improve their overall health." Obesity is one of the most pressing health challenges in the U.S., yet many people still struggle to access effective treatment. By combining Currax's clinical leadership in obesity care with GoodRx's reach and reputation for affordability, this collaboration removes a major barrier for patients who may not otherwise have access to FDA-approved medications. Together, the two companies are helping more people take control of their health with greater confidence and fewer hurdles. "Though millions of Americans struggle with obesity, weight management medications can be cost-prohibitive—with or without insurance—causing many people to delay or abandon prescribed treatments. These types of access and affordability challenges are why many pharmaceutical companies partner with GoodRx to reduce friction," said Dorothy Gemmell, Chief Commercial Officer at GoodRx. "By working with Currax to help consumers save money on Contrave, we're helping close this gap and delivering a simple affordability solution that improves access to a life-changing medication." Contrave is an FDA-approved, prescription-only oral medication for adults with obesity or those who are overweight with weight-related medical problems, used as an adjunct to a reduced-calorie diet and increased physical activity. For more information or to access the GoodRx Contrave savings card, visit: *Program benefit maximums and eligibility restrictions may apply. About CurraxCurrax Pharmaceuticals LLC is a specialty pharmaceutical business focused on addressing the #1 and #2 causes of preventable death in the United States, smoking and obesity. Currax distributes a range of both branded and generic pharmaceutical products, including CONTRAVE® (naltrexone HCl/bupropion HCl), ONZETRA® Xsail® (sumatriptan nasal powder), Silenor® (doxepin), Treximet®, (sumatriptan/naproxen sodium), and the authorized generic of Treximet®. For more information, please visit About CONTRAVE: CONTRAVE®, is an extended-release fixed dose combination of naltrexone and bupropion (naltrexone HCL/bupropion HCL) indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes. For full Prescribing Information, including BOXED Warning and Medication Guide, please go to Media Contactcurrax@ View original content to download multimedia: SOURCE Currax Pharmaceuticals LLC Melden Sie sich an, um Ihr Portfolio aufzurufen.
Axios
2 hours ago
- Axios
DOGE makes its way into biotech IPO filings
DOGE cuts are leading to new warnings in filings from biotech and health-care companies looking to IPO stateside. The big picture: Uncertainty is a deal killer. According to data from Renaissance Capital, there have been just four biotech IPOs this year that have raised over $50 million — down from 10 in the same period last year. Venture bets are slowing too. Driving the news: Carlsmed, a personalized spine surgery company backed by B Capital Group and U.S. Venture Partners warned in its prospectus that "the current U.S. presidential administration" has issued policies to cut headcount and budgets in agencies including the FDA. "It remains unclear the degree to which these efforts may limit or otherwise adversely affect the FDA's ability to conduct routine activities," it continued. Sixth Street-backed cancer diagnostics company, Caris Life Sciences, which went public in late June, said this: "The current Trump administration is pursuing policies to reduce regulations and expenditures across government including at HHS, the FDA, CMS, and related agencies," Caris' prospectus read. "These actions ... may propose policy changes that create additional uncertainty for our business. Zoom out: Though Carlsmed says it's "unclear the degree to which" the cuts will affect the FDA's ability to conduct routine activity, those in the space already feel the effects. The FDA told KalVista Pharmaceuticals last month that the agency would miss a deadline in approving a drug for potentially life-threatening genetic disorders — marking what appears to be the first time a review had to be extended over DOGE cuts. Verve Therapeutics, in a filing explaining its rationale for selling to Eli Lilly for $1.3 billion, noted that Peter Marks resignation in March as director of the FDA played a role in its move to sell rather than raise additional capital.
Yahoo
2 hours ago
- Yahoo
Ritz Crackers are Being Recalled Nationwide for This Life-Threatening Reason—Here's What to Know
Ritz Crackers are Being Recalled Nationwide for This Life-Threatening Reason—Here's What to Know originally appeared on Parade. Product recalls are never good news. But when they happen, it's on us as consumers to check our kitchens and make sure the foods we're eating aren't part of an affected batch. Recalls can be issued for all kinds of reasons—but faulty packaging, contamination or missing ingredients on a label are some of the most common ones. On July 8, Mondelēz Global LLC announced a voluntary recall of four carton sizes of RITZ Peanut Butter Cracker Sandwiches. The affected products were made in the U.S. and sold to the FDA notice, the recall includes 8-pack, 20-pack and 40-pack cartons of RITZ Peanut Butter Cracker Sandwiches, as well as the 20-pack RITZ Filled Cracker Sandwich Variety Pack. The issue? Some individually wrapped packs may be mislabeled as the Cheese variety, even though they actually contain the Peanut Butter variety. It's important to note that anyone with a peanut allergy or severe sensitivity could be at risk of a serious—or even life-threatening—allergic reaction if they consume these products. However, the FDA clarified that all affected outer cartons are labeled correctly and include an allergen advisory stating the product 'contains peanuts.' To help you identify the products at home, you can find full product descriptions, 'Best When Used By' dates and UPC codes here, as well as affected product images here. You can also locate a breakdown of what the product info grid might look like on the incorrectly labeled individually wrapped packages to the notice, this is a precautionary recall. No other RITZ products or Mondelēz Global LLC products are affected, and in a huge relief, there have been zero reports of injury or illness linked to it. The recall was initiated after Mondelēz Global LLC discovered that film packaging rolls used for individually wrapped peanut butter products may have defects due to a supplier error. According to the notice, 'corrective actions are being taken to help ensure this issue does not recur.' Just to be clear, cartons with only RITZ Cheese Cracker Sandwiches are not part of this recall. And if your RITZ Peanut Butter or RITZ Filled Cracker Sandwich Variety Pack has a different 'Best When Used By' date or plant code than the ones listed here, you're safe. If you have a peanut allergy, it's recommended to discard any of the affected products immediately or return them to the place of purchase for a refund. You can call the company anytime at 1-844-366-1171, or reach a Consumer Relations specialist Monday through Friday, 9 am to 6 pm Crackers are Being Recalled Nationwide for This Life-Threatening Reason—Here's What to Know first appeared on Parade on Jul 9, 2025 This story was originally reported by Parade on Jul 9, 2025, where it first appeared.
